These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 17043288)

  • 1. Futility of positron emission tomography and other modalities in the initial radiographic screening of patients with melanoma.
    Miranda EP
    Arch Surg; 2006 Oct; 141(10):1050. PubMed ID: 17043288
    [No Abstract]   [Full Text] [Related]  

  • 2. Futility of fluorodeoxyglucose F 18 positron emission tomography in initial evaluation of patients with T2 to T4 melanoma.
    Clark PB; Soo V; Kraas J; Shen P; Levine EA
    Arch Surg; 2006 Mar; 141(3):284-8. PubMed ID: 16549694
    [TBL] [Abstract][Full Text] [Related]  

  • 3. F-18 fluorodeoxy-D-glucose positron emission tomography scan in the initial evaluation of patients with a primary melanoma thicker than 4 mm.
    Maubec E; Lumbroso J; Masson F; Suciu V; Kolb F; Mamelle G; Cavalcanti A; Boitier F; Spatz A; Aupérin A; Leboulleux S; Avril MF
    Melanoma Res; 2007 Jun; 17(3):147-54. PubMed ID: 17505260
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Desmoplastic malignant melanoma evaluated with 18F-fluorodeoxyglucose positron emission tomography-computed tomography and sentinel lymph node biopsy.
    Jung JY; Roh MR; Chung HJ; Chung KY
    J Eur Acad Dermatol Venereol; 2008 Jan; 22(1):126-7. PubMed ID: 18181996
    [No Abstract]   [Full Text] [Related]  

  • 5. Positron emission tomography/computed tomography in melanoma.
    Bourgeois AC; Chang TT; Fish LM; Bradley YC
    Radiol Clin North Am; 2013 Sep; 51(5):865-79. PubMed ID: 24010910
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sentinel lymph node excision and positron emission tomography and computed tomography in the initial stage of malignant melanoma.
    Hafner J
    Dermatol Surg; 2010 Dec; 36(12):2082-3. PubMed ID: 21126282
    [No Abstract]   [Full Text] [Related]  

  • 7. Inefficacy of F-18 fluorodeoxy-D-glucose-positron emission tomography scans for initial evaluation in early-stage cutaneous melanoma.
    Wagner JD; Schauwecker D; Davidson D; Logan T; Coleman JJ; Hutchins G; Love C; Wenck S; Daggy J
    Cancer; 2005 Aug; 104(3):570-9. PubMed ID: 15977211
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ultrasound pre sentinel node dissection.
    Schäfer-Hesterberg G; Voit C
    Melanoma Res; 2008 Feb; 18(1):68-9. PubMed ID: 18227711
    [No Abstract]   [Full Text] [Related]  

  • 9. Contribution of whole body F-18-FDG-PET and lymphoscintigraphy to the assessment of regional and distant metastases in cutaneous malignant melanoma. A pilot study.
    Klein M; Freedman N; Lotem M; Marciano R; Moshe S; Gimon Z; Chisin R
    Nuklearmedizin; 2000; 39(3):56-61. PubMed ID: 10834191
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Melanoma imaging with highly specific PET probes: ready for prime time?
    Minn H; Vihinen P
    J Nucl Med; 2011 Jan; 52(1):5-7. PubMed ID: 21149485
    [No Abstract]   [Full Text] [Related]  

  • 11. Level of fluorodeoxyglucose uptake predicts risk for recurrence in melanoma patients presenting with lymph node metastases.
    Bastiaannet E; Hoekstra OS; Oyen WJ; Jager PL; Wobbes T; Hoekstra HJ
    Ann Surg Oncol; 2006 Jul; 13(7):919-26. PubMed ID: 16788752
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lymphatic mapping and sentinel lymphadenectomy in primary cutaneous melanoma.
    Scheri RP; Essner R
    Expert Rev Anticancer Ther; 2006 Jul; 6(7):1105-10. PubMed ID: 16831081
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Routine positron emission tomography and positron emission tomography/computed tomography in melanoma staging with positive sentinel node biopsy is of limited benefit.
    Constantinidou A; Hofman M; O'Doherty M; Acland KM; Healy C; Harries M
    Melanoma Res; 2008 Feb; 18(1):56-60. PubMed ID: 18227709
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Complete pathologic response after neoadjuvant treatment with vemurafenib for malignant melanoma.
    Kaidar-Person O; Eran A; Bar-Sela G
    J Am Acad Dermatol; 2014 Feb; 70(2):e39-41. PubMed ID: 24438978
    [No Abstract]   [Full Text] [Related]  

  • 15. [Sentinel node biopsy for malignant melanoma. Technical details and clinical results on 390 patients].
    Caggiati A; Migliano E; Potenza C; Gabrielli F; Tartaglione G; Pacchiarotti A; Ruatti P; Puddu P
    Minerva Chir; 2002 Aug; 57(4):481-7. PubMed ID: 12145579
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Influence of selected clinical features on detection of sentinel node in patients with skin melanoma].
    Nejc D; Piekarski J; Jeziorski A
    Przegl Lek; 2005; 62(12):1427-30. PubMed ID: 16786765
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The sentinel lymph node: more than just another blue lymph node.
    Wagner JD; Sondak VK
    Cancer; 2003 Apr; 97(8):1821-3. PubMed ID: 12673706
    [No Abstract]   [Full Text] [Related]  

  • 18. Regional lymph node assessment for conjunctival melanoma: sentinel lymph node biopsy and positron emission tomography.
    Esmaeli B
    Br J Ophthalmol; 2008 Apr; 92(4):443-5. PubMed ID: 18369054
    [No Abstract]   [Full Text] [Related]  

  • 19. Three-dimensional visualisation of lymphatic drainage patterns in patients with cutaneous melanoma.
    Reynolds HM; Dunbar PR; Uren RF; Blackett SA; Thompson JF; Smith NP
    Lancet Oncol; 2007 Sep; 8(9):806-12. PubMed ID: 17643351
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sentinel lymph node mapping in the management of high risk malignant melanoma.
    Donckier V; Vereecken P; Blocklet D; Laporte M; Velu T; Heenen M; Van Geertruyden J
    Acta Chir Belg; 1999 Dec; 99(6):295-8. PubMed ID: 10674132
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.